Have you been recently diagnosed with Acute Lymphoblastic Leukemia? If so, you may be able to take part in a research study to help us learn more about the effects of using Tyrosine Kinase Inhibitor (TKI), steroids and blinatumomab versus treatment with steroids, Tyrosine Kinase Inhibitor (TKI) and chemotherapy.

Have you been diagnosed with cancer or a benign disease that is being evaluated for cancer for which you may receive treatment? If so, you may be able to take part in a research study that collects biospecimens (e.g. blood, saliva, tissue, etc) and health information to better understand how cancers develop and affect the body,]. If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

The purpose of this study is to find out if treatment with the study drug, Bexmarilimab, along with standard of care can help with your type of cancer.

The purpose of this study is to learn more about the safety and effectiveness of the study drug (INCB057643) as monotherapy for participants with relapsed or refractory myelofibrosis.

If you or your child has been diagnosed with acute lymphoblastic leukemia (ALL), you or they might be able to take part in a research study. This study aims to understand why there are differences in outcomes in adolescents and young adults treated for ALL.

This is a research study for people diagnosed with AML. The purpose of this study is to see if the treatment of a combination of two drugs (cytarabine liposome therapy) and adding a third drug (pomalidomide) in different doses is more effective.

The purpose of this study is to better understand how young adults (ages 18 - 39) who have had cancer use entertainment media during and after cancer treatment.

Have you been diagnosed with Leukemia and are looking for another treatment option? In this study we are looking to see if the study drug DSP-5336 can help control Leukemia or achieve remission.

This is a registry of childhood, adolescent, and young adult patients with cancer. This registry is for anyone diagnosed with cancer before the age of 40 years to establish a UNC-based resource for the prospective study of the long-term, treatment-related effects, particularly the early aging effects, of cancer and its treatment.

To evaluate whether early drug treatment extends overall survival compared with delayed drug treatment with high-risk (chronic lymphocytic leukemia [CLL] newly diagnosed asymptomatic CLL/SLL patients.